{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T05:13:23Z","timestamp":1692508403492},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2009,6,19]],"date-time":"2009-06-19T00:00:00Z","timestamp":1245369600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1007\/s00105-008-1680-2","type":"journal-article","created":{"date-parts":[[2009,6,17]],"date-time":"2009-06-17T16:29:50Z","timestamp":1245256190000},"page":"633-640","source":"Crossref","is-referenced-by-count":2,"title":["Therapieoptimierung bei schweren bull\u00f6sen Autoimmundermatosen"],"prefix":"10.1007","volume":"60","author":[{"given":"E.","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,6,19]]},"reference":[{"key":"1680_CR1","first-page":"363","volume":"142","author":"Benoit","year":"2007","unstructured":"Benoit S, Br\u00f6cker EB, Schmidt E (2007) Current treatment of pemphigus. G Ital Dermatol Venereol 142:363\u2013380","journal-title":"G Ital Dermatol Venereol"},{"key":"1680_CR2","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1365-2133.2003.05665.x","volume":"149","author":"Harman","year":"2003","unstructured":"Harman KE, Albert S, Black MM (2003) Guidelines for the management of pemphigus vulgaris. Br J Dermatol 149:926\u2013937","journal-title":"Br J Dermatol"},{"key":"1680_CR3","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1001\/archderm.138.3.380","volume":"138","author":"Kirtschig","year":"2002","unstructured":"Kirtschig G, Murrell D, Wojnarowska F, Khumalo N (2002) Interventions for mucous membrane pemphigoid\/cicatricial pemphigoid and epidermolysis bullosa acquisita: a systematic literature review. Arch Dermatol 138:380\u2013384","journal-title":"Arch Dermatol"},{"key":"1680_CR4","doi-asserted-by":"crossref","unstructured":"Martin LK, Werth V, Villanueva E et al (2009) Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev CD006263","DOI":"10.1002\/14651858.CD006263.pub2"},{"key":"1680_CR5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00347-008-1700-8","volume":"105","author":"Meyer-ter-Vehn","year":"2008","unstructured":"Meyer-ter-Vehn T, Schmidt E, Zillikens D, Geerling G (2008) Mucous membrane pemphigoid with ocular involvement. Part\u00a0II: therapy. Ophthalmologe 105:405\u2013419","journal-title":"Ophthalmologe"},{"key":"1680_CR6","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1610-0378.2005.04747.x","volume":"3","author":"Rose","year":"2005","unstructured":"Rose E, Wever S, Zilliken D et al (2005) Intravenous dexamethasone-cyclophosphamide pulse therapy in comparison with oral methylprednisolone-azathioprine therapy in patients with pemphigus: results of a multicenter prospectively randomized study. J Dtsch Dermatol Ges 3:200\u2013206","journal-title":"J Dtsch Dermatol Ges"},{"key":"1680_CR7","first-page":"199","volume":"50","author":"Pasricha","year":"1984","unstructured":"Pasricha JS, Ramji G (1984) Pulse therapy with dexamethasone-cyclophosphamide in pemphigus. Indian J Dermatol Venereol Leprol 50:199\u2013203","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"1680_CR8","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1001\/archderm.142.11.1447","volume":"142","author":"Beissert","year":"2006","unstructured":"Beissert S, Werfel T, Frieling U et al (2006) A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol 142:1447\u20131454","journal-title":"Arch Dermatol"},{"key":"1680_CR9","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaad.2007.05.024","volume":"57","author":"Chams-Davatchi","year":"2007","unstructured":"Chams-Davatchi C, Esmaili N, Daneshpazhooh M et al (2007) Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol 57:622\u2013628","journal-title":"J Am Acad Dermatol"},{"key":"1680_CR10","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0190-9622(89)80148-3","volume":"20","author":"Tappeiner","year":"1989","unstructured":"Tappeiner G, Steiner A (1989) High-dosage intravenous gamma globulin: therapeutic failure in pemphigus and pemphigoid. J Am Acad Dermatol 20:684\u2013685","journal-title":"J Am Acad Dermatol"},{"key":"1680_CR11","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0190-9622(08)80783-9","volume":"22","author":"Humbert","year":"1990","unstructured":"Humbert P, Derancourt C, Aubin F, Agache P (1990) Effects of intravenous gamma-globulin in pemphigus. J Am Acad Dermatol 22:326","journal-title":"J Am Acad Dermatol"},{"key":"1680_CR12","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jaad.2006.06.029","volume":"56","author":"Segura","year":"2007","unstructured":"Segura S, Iranzo P, Martinez-de Pablo I et al (2007) High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases. J Am Acad Dermatol 56:960\u2013967","journal-title":"J Am Acad Dermatol"},{"key":"1680_CR13","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1067\/mjd.2000.108366","volume":"43","author":"Engineer","year":"2000","unstructured":"Engineer L, Bhol KC, Ahmed AR (2000) Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris. J Am Acad Dermatol 43:1049\u20131057","journal-title":"J Am Acad Dermatol"},{"key":"1680_CR14","doi-asserted-by":"crossref","unstructured":"Ishii N, Hashimoto K, Zillikens D, Ludwig RJ (2009) High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases. Ann N Y Acad Sci (in press)","DOI":"10.1007\/s12016-009-8153-y"},{"key":"1680_CR15","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1365-2133.1996.tb03913.x","volume":"135","author":"Wever","year":"1996","unstructured":"Wever S, Zillikens D, Brocker EB (1996) Successful treatment of refractory mucosal lesions of pemphigus vulgaris using intravenous gammaglobulin as adjuvant therapy. Br J Dermatol 135:862\u2013863","journal-title":"Br J Dermatol"},{"key":"1680_CR16","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1067\/mjd.2001.116339","volume":"45","author":"Ahmed","year":"2001","unstructured":"Ahmed AR (2001) Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 45:679\u2013690","journal-title":"J Am Acad Dermatol"},{"key":"1680_CR17","first-page":"48","volume":"84","author":"Herzog","year":"2004","unstructured":"Herzog S, Schmidt E, Goebeler M et al (2004) Serum levels of autoantibodies to desmoglein 3 in patients with therapy-resistant pemphigus vulgaris successfully treated with adjuvant intravenous immunoglobulins. Acta Derm Venereol 84:48\u201352","journal-title":"Acta Derm Venereol"},{"key":"1680_CR18","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaad.2008.09.052","volume":"60","author":"Amagai","year":"2009","unstructured":"Amagai M, Ikeda S, Shimizu H et al (2009) A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol 60:595\u2013603","journal-title":"J Am Acad Dermatol"},{"key":"1680_CR19","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.ophtha.2003.11.012","volume":"111","author":"Sami","year":"2004","unstructured":"Sami N, Letko E, Androudi S et al (2004) Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up. Ophthalmology 111:1380\u20131382","journal-title":"Ophthalmology"},{"key":"1680_CR20","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1046\/j.1365-2249.2002.01942.x","volume":"129","author":"Sami","year":"2002","unstructured":"Sami N, Bhol KC, Ahmed AR (2002) Treatment of oral pemphigoid with intravenous immunoglobulin as monotherapy. Long-term follow-up: influence of treatment on antibody titres to human alpha6 integrin. Clin Exp Immunol 129:533\u2013540","journal-title":"Clin Exp Immunol"},{"key":"1680_CR21","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/intimm\/dxm052","volume":"19","author":"Blank","year":"2007","unstructured":"Blank M, Anafi L, Zandman-Goddard G et al (2007) The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Int Immunol 19:857\u2013865","journal-title":"Int Immunol"},{"key":"1680_CR22","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.1154315","volume":"320","author":"Anthony","year":"2008","unstructured":"Anthony RM, Nimmerjahn F, Ashline DJ et al (2008) Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320:373\u2013376","journal-title":"Science"},{"key":"1680_CR23","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1172\/JCI24394","volume":"115","author":"Li","year":"2005","unstructured":"Li N, Zhao M, Hilario-Vargas J et al (2005) Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest 115:3440\u20133450","journal-title":"J Clin Invest"},{"key":"1680_CR24","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00109-008-0366-7","volume":"86","author":"Sesarman","year":"2008","unstructured":"Sesarman A, Sitaru AG, Olaru F et al (2008) Neonatal Fc receptor deficiency protects from tissue injury in experimental epidermolysis bullosa acquisita. J Mol Med 86:951\u2013959","journal-title":"J Mol Med"},{"key":"1680_CR25","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0002-9440(10)61239-4","volume":"167","author":"Arredondo","year":"2005","unstructured":"Arredondo J, Chernyavsky AI, Karaouni A, Grando SA (2005) Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in Pemphigus. Am J Pathol 167:1531\u20131544","journal-title":"Am J Pathol"},{"key":"1680_CR26","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1126\/science.1129594","volume":"313","author":"Kaneko","year":"2006","unstructured":"Kaneko Y, Nimmerjahn F, Ravetch JV et al (2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313:670\u2013673","journal-title":"Science"},{"key":"1680_CR27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.autrev.2006.08.011","volume":"6","author":"Katz","year":"2007","unstructured":"Katz U, Achiron A, Sherer Y, Shoenfeld Y (2007) Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 6:257\u2013259","journal-title":"Autoimmun Rev"},{"key":"1680_CR28","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.1610-0387.2003.02028.x","volume":"1","author":"Enk","year":"2003","unstructured":"Enk A, Hertl M, Messer G et al (2003) The use of high dose intravenous immunoglobulins in dermatology. J Dtsch Dermatol Ges 1:183\u2013190","journal-title":"J Dtsch Dermatol Ges"},{"key":"1680_CR29","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.intimp.2005.11.002","volume":"6","author":"Daoud","year":"2006","unstructured":"Daoud YJ, Amin KG (2006) Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases. Int Immunopharmacol 6:600\u2013606","journal-title":"Int Immunopharmacol"},{"key":"1680_CR30","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1172\/JCI117349","volume":"94","author":"Amagai","year":"1994","unstructured":"Amagai M, Hashimoto T, Shimizu N, Nishikawa T (1994) Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest 94:59\u201367","journal-title":"J Clin Invest"},{"key":"1680_CR31","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1172\/JCI116856","volume":"92","author":"Liu","year":"1993","unstructured":"Liu Z, Diaz LA, Troy JL et al (1993) A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 92:2480\u20132488","journal-title":"J Clin Invest"},{"key":"1680_CR32","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJM198205203062001","volume":"306","author":"Anhalt","year":"1982","unstructured":"Anhalt GJ, Labib RS, Voorhees JJ et al (1982) Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 306:1189\u20131196","journal-title":"N Engl J Med"},{"key":"1680_CR33","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/archderm.136.2.174","volume":"136","author":"Schmidt","year":"2000","unstructured":"Schmidt E, Obe K, Brocker EB, Zillikens D (2000) Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 136:174\u2013478","journal-title":"Arch Dermatol"},{"key":"1680_CR34","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2133.1978.tb01631.x","volume":"98","author":"Cotterill","year":"1978","unstructured":"Cotterill JA, Barker DJ, Millard LG (1978) Plasma exchange in the treatment of pemphigus vulgaris. Br J Dermatol 98:243","journal-title":"Br J Dermatol"},{"key":"1680_CR35","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/archderm.1988.01670110019004","volume":"124","author":"Guillaume","year":"1988","unstructured":"Guillaume JC, Roujeau JC, Morel P et al (1988) Controlled study of plasma exchange in pemphigus. Arch Dermatol 124:1659\u20131663","journal-title":"Arch Dermatol"},{"key":"1680_CR36","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1517\/13543784.9.9.2017","volume":"9","author":"Braun","year":"2000","unstructured":"Braun N, Bosch T (2000) Immunoadsorption, current status and future developments. Expert Opin Investig Drugs 9:2017\u20132038","journal-title":"Expert Opin Investig Drugs"},{"key":"1680_CR37","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000090659","volume":"212","author":"Eming","year":"2006","unstructured":"Eming R, Rech J, Barth S et al (2006) Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption. Dermatology 212:177\u2013187","journal-title":"Dermatology"},{"key":"1680_CR38","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2230.2006.02220.x","volume":"31","author":"Shimanovich","year":"2006","unstructured":"Shimanovich I, Herzog S, Schmidt E et al (2006) Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption. Clin Exp Dermatol 31:768\u2013774","journal-title":"Clin Exp Dermatol"},{"key":"1680_CR39","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1046\/j.1365-2133.2003.05302.x","volume":"148","author":"Schmidt","year":"2003","unstructured":"Schmidt E, Klinker E, Opitz A et al (2003) Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. Br J Dermatol 148:1222\u20131229","journal-title":"Br J Dermatol"},{"key":"1680_CR40","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1046\/j.1365-2133.2003.05513.x","volume":"149","author":"Luftl","year":"2003","unstructured":"Luftl M, Stauber A, Mainka A et al (2003) Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber. Br J Dermatol 149:598\u2013605","journal-title":"Br J Dermatol"},{"key":"1680_CR41","doi-asserted-by":"crossref","unstructured":"Schmidt E, Zillikens D (2009) Immunoadsorption treatment for autoimmune bullous diseases. In: Braun N (ed) Fundamentals and applications of immunoadsorption. UNI-MED, Bremen (in press)","DOI":"10.1007\/978-3-540-29316-3_46"},{"key":"1680_CR42","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000187431","volume":"218","author":"Pfutze","year":"2009","unstructured":"Pfutze M, Eming R, Kneisel A et al (2009) Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab. Dermatology 218:237\u2013245","journal-title":"Dermatology"},{"key":"1680_CR43","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1365-2133.2007.08358.x","volume":"158","author":"Shimanovich","year":"2008","unstructured":"Shimanovich I, Nitschke M, Rose C et al (2008) Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br J Dermatol 158:382\u2013388","journal-title":"Br J Dermatol"},{"key":"1680_CR44","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/j.1610-0387.2007.06342.x","volume":"5","author":"Zillikens","year":"2007","unstructured":"Zillikens D, Derfler K, Eming R et al (2007) Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases. J Dtsch Dermatol Ges 5:881\u2013887","journal-title":"J Dtsch Dermatol Ges"},{"key":"1680_CR45","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1586\/17469872.3.3.259","volume":"3","author":"Schmidt","year":"2008","unstructured":"Schmidt E, Goebeler M (2008) CD20-directed therapy in autoimmune diseases involving the skin: role of rituximab. Expert Rev Dermatol 3:259\u2013278","journal-title":"Expert Rev Dermatol"},{"key":"1680_CR46","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/jid.2008.192","volume":"129","author":"Nagel","year":"2009","unstructured":"Nagel A, Hertl M, Eming R (2009) B-cell-directed therapy for inflammatory skin diseases. J Invest Dermatol 129:289\u2013301","journal-title":"J Invest Dermatol"},{"key":"1680_CR47","doi-asserted-by":"crossref","unstructured":"Schmidt E, Goebeler M, Zillikens D (2009) Rituximab in severe pemphigus. Ann N Y Acad Sci (in press)","DOI":"10.1111\/j.1749-6632.2009.04744.x"},{"key":"1680_CR48","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMoa062930","volume":"355","author":"Ahmed","year":"2006","unstructured":"Ahmed AR, Spigelman Z, Cavacini LA, Posner MR (2006) Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 355:1772\u20131779","journal-title":"N Engl J Med"},{"key":"1680_CR49","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa067752","volume":"357","author":"Joly","year":"2007","unstructured":"Joly P, Mouquet H, Roujeau JC et al (2007) A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 357:545\u2013552","journal-title":"N Engl J Med"},{"key":"1680_CR50","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/archderm.143.8.1033","volume":"143","author":"Cianchini","year":"2007","unstructured":"Cianchini G, Corona R, Frezzolini A et al (2007) Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. Arch Dermatol 143:1033\u20131038","journal-title":"Arch Dermatol"},{"key":"1680_CR51","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2133.2006.07646.x","volume":"156","author":"Schmidt","year":"2007","unstructured":"Schmidt E, Seitz CS, Benoit S et al (2007) Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 156:352\u2013356","journal-title":"Br J Dermatol"},{"key":"1680_CR52","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1610-0387.2007.06602.x","volume":"6","author":"Hertl","year":"2008","unstructured":"Hertl M, Zillikens D, Borradori L et al (2008) Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges 6:366\u2013373","journal-title":"J Dtsch Dermatol Ges"},{"key":"1680_CR53","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrd2085","volume":"5","author":"Browning","year":"2006","unstructured":"Browning JL (2006) B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 5:564\u2013576","journal-title":"Nat Rev Drug Discov"},{"key":"1680_CR54","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1038\/jid.2008.178","volume":"128","author":"Mouquet","year":"2008","unstructured":"Mouquet H, Musette P, Gougeon ML et al (2008) B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest Dermatol 128:2859\u20132869","journal-title":"J Invest Dermatol"},{"key":"1680_CR55","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1038\/jid.2008.172","volume":"128","author":"Eming","year":"2008","unstructured":"Eming R, Nagel A, Wolff-Franke S et al (2008) Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol 128:2850\u20132858","journal-title":"J Invest Dermatol"},{"key":"1680_CR56","doi-asserted-by":"crossref","unstructured":"Nagel A, Podstawa E, Eickmann M et al (2009) Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris. J Invest Dermatol (bisher nur online erschienen)","DOI":"10.1038\/jid.2009.27"},{"key":"1680_CR57","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","volume":"113","author":"Carson","year":"2009","unstructured":"Carson KR, Evens AM, Richey EA et al (2009) Progressive multifocal leukoencephalopathy following rituximab therapy in HIV negative patients: a report of 57 cases from the Research on Adverse Drug Event and Reports (RADAR) project. Blood 113:4834\u20134840","journal-title":"Blood"},{"key":"1680_CR58","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s12016-007-8021-6","volume":"34","author":"Schmidt","year":"2008","unstructured":"Schmidt E, Brocker EB, Goebeler M (2008) Rituximab in treatment-resistant autoimmune blistering skin disorders. Clin Rev Allergy Immunol 34:56\u201364","journal-title":"Clin Rev Allergy Immunol"},{"key":"1680_CR59","first-page":"910","volume":"10","author":"Schmidt","year":"2008","unstructured":"Schmidt E, Kramer J, Ang\u00fcn O et al (2008) Behandlung des schweren Pemphigus mit der Kombination von Immunadsorption und Rituximab. J Dtsch Dermatol Ges 10:910 (Abstrakt)","journal-title":"J Dtsch Dermatol Ges"},{"key":"1680_CR60","first-page":"434","volume":"5","author":"Bertram","year":"2009","unstructured":"Bertram F, Brocker EB, Zillikens D, Schmidt E (2009) Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges 5:434\u2013440","journal-title":"J Dtsch Dermatol Ges"},{"key":"1680_CR61","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/archderm.138.3.385","volume":"138","author":"Khumalo","year":"2002","unstructured":"Khumalo NP, Murrell DF, Wojnarowska F, Kirtschig G (2002) A systematic review of treatments for bullous pemphigoid. Arch Dermatol 138:385\u2013389","journal-title":"Arch Dermatol"},{"key":"1680_CR62","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1046\/j.1439-0353.2004.04702.x-i1","volume":"2","author":"Goebeler","year":"2004","unstructured":"Goebeler M, Sitaru C, Zillikens D (2004) Blistering autoimmune dermatoses (II): therapy. J Dtsch Dermatol Ges 2:774\u2013791 (quiz 792\u2013793)","journal-title":"J Dtsch Dermatol Ges"},{"key":"1680_CR63","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/j.1365-4632.2006.02750.x","volume":"45","author":"Mulyowa","year":"2006","unstructured":"Mulyowa GK, Jaeger G, Kabakyenga J et al (2006) Autoimmune subepidermal blistering diseases in Uganda: correlation of autoantibody class with age of patients. Int J Dermatol 45:1047\u20131052","journal-title":"Int J Dermatol"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-008-1680-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-008-1680-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-008-1680-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T03:37:41Z","timestamp":1558582661000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-008-1680-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,19]]},"references-count":63,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["1680"],"URL":"https:\/\/doi.org\/10.1007\/s00105-008-1680-2","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,19]]}}}